Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1992-7-21
|
pubmed:abstractText |
The magnitude and duration of protection against exercise-induced asthma (EIA) afforded by salbutamol and the new, long-acting beta 2-agonist, formoterol, were compared in a double-blind, placebo-controlled crossover study. Twelve children with asthma and EIA (greater than 25% fall from baseline at a pretrial exercise test) were studied on 3 different days receiving, in random order, either formoterol, 12 micrograms, salbutamol, 200 micrograms, or placebo by inhalation. The effect on EIA was evaluated by standardized treadmill-exercise tests repeated at the following times after medication: 1/2 hour (test 1), 3 hours (test 2), and, if the trial drug still demonstrated an effect, 5 1/2 hours (test 3) and 8 hours (test 4). The mean (SD) maximum percent fall in FEV1 at the pretrial test was 45% (14%). Placebo treatment had no effect on EIA. The mean (SD) maximum percent fall in FEV1 was 44% (14%) (test 1) and 39% (13%) (test 2) (not significant). Salbutamol offered good protection against EIA after 1/2 hour (percent fall in FEV1, 18% [18%]; p less than 0.02) but was not significantly different from that of placebo after 3 hours, 39% (13%) fall in FEV1. Formoterol blocked EIA in all the children and demonstrated a significant effect in most children for at least 8 hours. The percent fall in FEV1 after the various tests were 8% (16%) (test 1), 10% (9%) (test 2), 18% (15%) (test 3), and 18% (7%) (test 4; N = 9) (all tests, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Albuterol,
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Ethanolamines,
http://linkedlifedata.com/resource/pubmed/chemical/formoterol
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0091-6749
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
89
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1176-82
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1351489-Administration, Inhalation,
pubmed-meshheading:1351489-Adolescent,
pubmed-meshheading:1351489-Adrenergic beta-Agonists,
pubmed-meshheading:1351489-Albuterol,
pubmed-meshheading:1351489-Asthma, Exercise-Induced,
pubmed-meshheading:1351489-Bronchodilator Agents,
pubmed-meshheading:1351489-Child,
pubmed-meshheading:1351489-Double-Blind Method,
pubmed-meshheading:1351489-Drug Evaluation,
pubmed-meshheading:1351489-Ethanolamines,
pubmed-meshheading:1351489-Exercise Test,
pubmed-meshheading:1351489-Humans,
pubmed-meshheading:1351489-Male,
pubmed-meshheading:1351489-Respiratory Function Tests,
pubmed-meshheading:1351489-Time Factors
|
pubmed:year |
1992
|
pubmed:articleTitle |
Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children.
|
pubmed:affiliation |
Department of Pediatrics, Kolding Sygehus, Kolding, Denmark.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|